Stability of correction: sagittal changes of pogonion (1 week to 1 year) · Adults (16 years of age or older) with an Angle Class III malocclusion (prominent lower front teeth); people with syndromes, clefts or…
Intraoral vertical ramus osteotomy (IVRO) showed no clear difference in stability of correction: sagittal changes of pogonion (1 week to 1… compared with sagittal split ramus osteotomy (SSRO); GRADE not reported.
1 finding from 1 review
Stability of correction: vertical changes of B-point (1 week to 1 year) · Adults (16 years of age or older) with an Angle Class III malocclusion (prominent lower front teeth); people with syndromes, clefts or…
Intraoral vertical ramus osteotomy (IVRO) showed no clear difference in stability of correction: vertical changes of B-point (1 week to 1… compared with sagittal split ramus osteotomy (SSRO); GRADE not reported.
1 finding from 1 review
Change in disability score · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Muscle strength · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Change in pulmonary function · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure severity · people with ADHD and epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · people with ADHD and epilepsy
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tear film stability · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found